Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotechnology Business
Ortho Biotech and Amgen Resolve Antitrust Litigation
August 2nd, 2008
Ortho Biotech Products, L.P., a Johnson & Johnson company, announced it has reached an agreement to settle its antitrust litigation with Amgen. In the litigation, Ortho Biotech alleged that discounts offered to oncology clinics on the Amgen products, Aranesp(R), Neupogen(R) and Neulasta(R), violated antitrust laws. Under terms of the agreement, Amgen will pay Ortho Biotech $200 million. The after-tax gain of approximately $120 million is expected to be recorded in the results of operations for Johnson & Johnson for the third quarter of 2008. Ortho Biotech is pleased with the agreement and the pending litigation in New Jersey District Court will be...
Source: Law & Health Weekly (2008-08-02)
|
